|
1
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Baldewijns MM, van Vlodrop IJH, Vermeulen
PB, Soetekouw PM, van Engeland M and de Bruïne AP: VHL and HIF
signalling in renal cell carcinogenesis. J Pathol. 221:125–138.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Motzer RJ, Mazumdar M, Bacik J, Berg W,
Amsterdam A and Ferrara J: Survival and prognostic stratification
of 670 patients with advanced renal cell carcinoma. J Clin Oncol.
17:2530–2540. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Escudier B, Eisen T, Porta C, Patard JJ,
Khoo V, Algaba F, Mulders P and Kataja V: ESMO Guidelines Working
Group: Renal cell carcinoma: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 23:(Suppl 7).
vii65–vii71. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Motzer RJ, Agarwal N, Beard C, Bolger GB,
Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock
SL, et al: NCCN clinical practice guidelines in oncology: Kidney
cancer. J Natl Compr Canc Netw. 7:618–630. 2009.PubMed/NCBI
|
|
6
|
Bellmunt J, Puente J, de Garcia Muro J,
Lainez N, Rodríguez C and Duran I: Spanish Society for Medical
Oncology: SEOM clinical guidelines for the treatment of renal cell
carcinoma. Clin Transl Oncol. 16:1043–1050. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Motzer RJ, Hutson TE, McCann L, Deen K and
Choueiri TK: Overall survival in renal-cell carcinoma with
pazopanib versus sunitinib. N Engl J Med. 370:1769–1770. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ghatalia P, Morgan CJ, Choueiri TK, Rocha
P, Naik G and Sonpavde G: Pancreatitis with vascular endothelial
growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol
Hematol. 94:136–145. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Russano M, Vincenzi B, Venditti O,
D'Onofrio L, Ratta R, Guida FM, Tonini G and Santini D: Pazopanib
and pancreatic toxicity: A case report. BMC Res Notes. 8:1962015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Motzer RJ, Hutson TE, Cella D, Reeves J,
Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, et
al: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
N Engl J Med. 369:722–731. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Suttle AB, Ball HA, Molimard M, Hutson TE,
Carpenter C, Rajagopalan D, Lin Y, Swann S, Amado R and Pandite L:
Relationships between pazopanib exposure and clinical safety and
efficacy in patients with advanced renal cell carcinoma. Br J
Cancer. 111:1909–1916. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sternberg CN, Davis ID, Mardiak J,
Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA,
Kavina A, et al: Pazopanib in locally advanced or metastatic renal
cell carcinoma: Results of a randomized phase III trial. J Clin
Oncol. 28:1061–1068. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Escudier B, Porta C, Bono P, Powles T,
Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins
R, et al: Randomized, controlled, double-blind, cross-over trial
assessing treatment preference for pazopanib versus sunitinib in
patients with metastatic renal cell carcinoma: PISCES Study. J Clin
Oncol. 32:1412–1418. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Santoni M, Conti A, De Giorgi U, Iacovelli
R, Pantano F, Burattini L, Muzzonigro G, Berardi R, Santini D and
Cascinu S: Risk of gastrointestinal events with sorafenib,
sunitinib and pazopanib in patients with solid tumors: A systematic
review and meta-analysis of clinical trials. Int J Cancer.
135:763–773. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sleijfer S, Ray-Coquard I, Papai Z, Le
Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marreaud S, De
Brauwer A, et al: Pazopanib, a multikinase angiogenesis inhibitor,
in patients with relapsed or refractory advanced soft tissue
sarcoma: A phase II study from the European organisation for
research and treatment of cancer-soft tissue and bone sarcoma group
(EORTC study 62043). J Clin Oncol. 27:3126–3132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen HX and Cleck JN: Adverse effects of
anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol.
6:465–477. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kawakubo K, Hata H, Kawakami H, Kuwatani
M, Kawahata S, Kubo K, Imafuku K, Kitamura S and Sakamoto N:
Pazopanib-Induced Severe Acute Pancreatitis. Case Rep Oncol.
8:356–358. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Amar S, Wu KJ and Tan WW:
Sorafenib-induced pancreatitis. Mayo Clin Proc. 82:5212007.
View Article : Google Scholar : PubMed/NCBI
|
